Stem Cell Gold Rush
By Jesse Reynolds,
Hartford Courant
| 08. 20. 2006
State Board Rife With Conflicts
Connecticut and a handful of other states are funding human embryonic stem cell research on their own, in reaction to the federal stalemate. Unfortunately, there are signs that Connecticut's $100 million program is rushing forward in a reckless and haphazard way, risking not just millions of taxpayer dollars but the reputation of a line of research that could alleviate suffering.
Although last summer's law creating the program has some admirable points, its key flaw is the composition of the grant-awarding committee. The law's requirements mean that two-thirds of the committee members are involved in stem cell research and likely to be interested in grants themselves.
For example, the board includes Xiangzhong "Jerry" Yang, the state's premier stem cell researcher. Last year, he threatened to move his work to China if the state did not pass the funding bill. Once he was on the committee, he made it clear that he'd be seeking big bucks. He's now applied for $5 million - from his own committee.
Moreover, because Connecticut has only two research universities, conflicts of interest are built in: Committee...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...